Trials / Unknown
UnknownNCT03730311
Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers
Phase Ib, Single-Centre, Placebo-Controlled Randomised Study of Safety, Tolerability and Pharmacokinetics of Elpida in Healthy HIV-Uninfected Volunteers
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Viriom · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
A randomized, placebo-controlled, once weekly dose for four weeks, double blind study in Healthy HIV-Uninfected Volunteers. Each of 3 consequent groups (120 mg, 200 mg and 280mg) enrolls 6 active and 2 placebo subjects.
Detailed description
The study aims to assess safety, tolerability and PK of once weekly administration of Elpida in different doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Elpida | elsulfavirine, capsules |
| DRUG | placebo | placebo |
Timeline
- Start date
- 2019-05-01
- Primary completion
- 2019-11-01
- Completion
- 2019-12-01
- First posted
- 2018-11-05
- Last updated
- 2019-05-20
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT03730311. Inclusion in this directory is not an endorsement.